INVESTIG. NEW DRUG TOX. FOR DRUGS TO TREAT ALZHEIMERS

调查。

• 批准号: 6346556
• 负责人: GERALD J SCHAEFER
• 金额: --
• 依托单位: MPI RESEARCH, LLC
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6346556
• 关键词: Alzheimer's disease; Rodentias; aging; brain disorder chemotherapy; dogs; drug screening /evaluation; toxicology

Efforts in developing and testing new drugs for the treatment of the cognitive impairment associated with Alzheimer's disease represent a major programmatic activity of NIA but are now hindered by the lack of access of many investigators to animal testing facilities. The present paucity of any compounds which can uniformly slow or reverse the progression of the disease or ameliorate the symptoms requires that every effort be made to facilitate the development and testing of new and compounds. The need to develop compounds for other aging-related diseases such as osteoporosis is also apparent. However, there are still gaps in our overall effort to facilitate the development and testing of new compounds. Specifically, resources are needed by investigators who are developing new compounds so that the potential adverse toxicological activity of the compounds can be evaluated before they can be taken into clinical trials. This is a very expensive process and is beyond the resources of almost all investigators. The purpose of this contract is to evaluate acute and chronic toxicity in rodents and dogs of drugs which are proposed to have potential use in the treatment of Alzheimer's disease and other aging-related diseases. The data generated from those studies will be used as part of the filing of an Investigational New Drug Application to the Food and Drug Administration in order to receive approval to use the drugs in humans. This will expand drug development efforts for Alzheimer's disease and other aging-related diseases to a larger and more diverse group of investigators.

开发和测试新药物以治疗与阿尔茨海默氏病有关的认知障碍的努力代表了NIA的一项主要程序活动，但由于缺乏许多研究人员进入动物测试设施而受到阻碍。 目前的任何化合物都可能均匀地降低或扭转疾病进展或改善症状，要求竭尽全力促进新的和化合物的开发和测试。对于其他与衰老有关的疾病（如骨质疏松症）开发化合物的需求也很明显。 但是，我们的整体努力仍然存在差距，以促进新化合物的开发和测试。 具体而言，正在开发新化合物的研究人员需要资源，以便可以在将它们带入临床试验之前对化合物的潜在不良毒理活性进行评估。 这是一个非常昂贵的过程，并且超出了几乎所有调查人员的资源。该合同的目的是评估啮齿动物和狗的急性和慢性毒性，这些药物被认为在治疗阿尔茨海默氏病和其他与衰老有关的疾病的治疗中有可能使用。 这些研究产生的数据将被用作向食品药品监督管理局提交研究新药申请的一部分，以获得批准以在人类中使用这些药物。这将扩大针对阿尔茨海默氏病和其他与衰老有关的疾病的药物开发工作，以扩大到更大，更多样化的研究者。

项目成果

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

• DOI: 10.1111/j.1527-3458.2005.tb00053.x
• 发表时间: 2006-06
• 期刊: CNS drug reviews
• 作者: I. Gozes;Bruce H. Morimoto;J. Tiong;A. Fox;K. Sutherland;D. Dangoor;Miriam Holser-Cochav;K. Vered;P. Newton;P. Aisen;Y. Matsuoka;C. V. van Dyck;L. Thal